Browse the evidence

GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.

GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.

Discontinuation of GLP-1 receptor agonists can lead to rapid weight regain and loss of cardiometabolic benefits.

Maintaining adherence to GLP-1 RA therapy is crucial for sustained weight loss and health benefits.

Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.

Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Single-set resistance training performed to failure elicits greater hypertrophy gains compared to submaximal effort, although differences are modest.

Practitioners may consider incorporating training to failure for enhanced muscle growth.

Both training to failure and submaximal effort result in similar increases in strength and local muscular endurance.

Both training methods can be effective for improving strength and endurance.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.

GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.

GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.

Practitioners can consider GLP-1RAs as effective options for managing obesity and glycemic control in patients.

GLP-1 receptor agonist patients experienced greater weight loss (7.8 kg) compared to controls (0.5 kg), with statistical significance (p<0.001).

Weight management strategies may be more effective in patients using GLP-1 receptor agonists.

UPFs increase the risk of chronic diseases and death.

Public health initiatives should address the risks associated with UPF consumption.

A 3-month regimen of nutrition counseling and high-intensity resistance training resulted in a 6.6% reduction in body fat and a 1.4% increase in muscle mass.

Practitioners can implement similar exercise and nutrition regimens to promote fat loss and muscle gain in breast cancer patients.

Participants demonstrated a 36.5% increase in composite load lifted across compound exercises.

Strength training protocols can effectively enhance lifting capacity in breast cancer survivors.

Increasing weekly sets may offer additional benefits for 1RM and vastus lateralis cross-sectional area.

Practitioners may consider increasing resistance training volume to enhance strength and muscle size.

All groups demonstrated improvements in the measured outcomes.

Resistance training is effective for improving strength and muscle outcomes in females.

GLP-1 medicines reduce food intake, body weight, insulin resistance and inflammation.

GLP-1 medicines can be considered for managing weight and metabolic health in patients with type 2 diabetes and obesity.

Incretin mimetics, including glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists, are first-line treatment options for type 2 diabetes and obesity.

Healthcare professionals should consider these agents as primary treatment options for managing type 2 diabetes and obesity.

Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg.

Semaglutide is the most effective GLP-1 receptor agonist for improving glycemic control and promoting weight loss in T2DM patients.

Emerging oral therapies could complement or serve as alternatives to approved injectable treatments for long-term weight management.

Practitioners should consider these oral therapies as viable options alongside injectables.

Preconception weight optimization in women with obesity is important to reduce maternal and fetal risks.

Practitioners should prioritize weight management in women with obesity planning for pregnancy.

Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.

These agonists may offer new treatment options for diabetes and obesity.

Weight loss of more than 10% may reduce obesity-associated cancer incidence.

Encouraging significant weight loss may be a viable strategy for reducing cancer risk in obese patients.

Semaglutide had substantial effects on multiple secondary alcohol-related and somatic outcomes.

Semaglutide may improve various aspects of health related to alcohol use disorder in addition to reducing drinking.

Semaglutide resulted in a similar reduction in body weight across frailty subgroups.

Semaglutide can be used effectively for weight management in patients with obesity-related HFpEF, regardless of frailty status.